We are live on ! Find out more
Adage Capital Partners

Adage Capital Partners Portfolio holdings

AUM $64.8B
1-Year Est. Return 42.7%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$64.8B
AUM Growth
-$1.23B
Cap. Flow
+$395M
Cap. Flow %
0.61%
Top 10 Hldgs %
28.4%
Holding
1,116
New
212
Increased
277
Reduced
389
Closed
160

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$330M
2
CTRA
Coterra Energy
CTRA
+$214M
3
BSX icon
Boston Scientific
BSX
+$204M
4
RBA icon
RB Global
RBA
+$183M
5
CVX icon
Chevron
CVX
+$131M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$190M
2
RPRX icon
Royalty Pharma
RPRX
+$187M
3
DOV icon
Dover
DOV
+$178M
4
BA icon
Boeing
BA
+$168M
5
DVN icon
Devon Energy
DVN
+$155M

Sector Composition

Rank Sector Weight
1 Technology 27.24%
2 Healthcare 15.45%
3 Financials 12.46%
4 Industrials 9.23%
5 Communication Services 8.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVVD icon
776
Invivyd
IVVD
$180M
$4.76M 0.01%
3,661,480
– –
RAPP
777
Rapport Therapeutics
RAPP
$1.95B
$4.69M 0.01%
150,000
– –
FWRD icon
778
Forward Air
FWRD
$482M
$4.63M 0.01%
277,069
+140,244
+102% +$3.41M
CBU icon
779
Community Bank
CBU
$3.53B
$4.5M 0.01%
76,766
+38,619
+101% +$2.36M
ASMB icon
780
Assembly Biosciences
ASMB
$506M
$4.47M 0.01%
161,000
– –
BLRK
781
Bluerock Acquisition Corp
BLRK
$232M
$4.46M 0.01%
+450,000
New +$4.45M
ORIC icon
782
Oric Pharmaceuticals
ORIC
$1.25B
$4.36M 0.01%
344,315
-204,685
-37% -$2.32M
KYTX icon
783
Kyverna Therapeutics
KYTX
$450M
$4.32M 0.01%
500,000
-1,166,666
-70% -$9.72M
ATRC icon
784
AtriCure
ATRC
$1.77B
$4.28M 0.01%
150,000
+39,790
+36% +$1.36M
PENN icon
785
PENN Entertainment
PENN
$2.74B
$4.27M 0.01%
284,008
-243,189
-46% -$3.38M
LW icon
786
Lamb Weston
LW
$6.82B
$4.23M 0.01%
100,000
-125,800
-56% -$5.61M
GLUE icon
787
Monte Rosa Therapeutics
GLUE
$1.92B
$4.11M 0.01%
+250,000
New +$4.78M
OLMA icon
788
Olema Pharmaceuticals
OLMA
$1.02B
$4.1M 0.01%
275,000
+65,000
+31% +$1.45M
PNFP icon
789
Pinnacle Financial Partners Inc
PNFP
$15.5B
$4.08M 0.01%
+47,383
New +$4.41M
BF.B icon
790
Brown-Forman Class B
BF.B
$12B
$4.03M 0.01%
152,432
-6,500
-4% -$175K
ALXO icon
791
ALX Oncology
ALXO
$273M
$4.01M 0.01%
+2,000,000
New +$3.81M
EPAM icon
792
EPAM Systems
EPAM
$4.69B
$3.97M 0.01%
29,300
-600
-2% -$103K
STZ icon
793
Constellation Brands
STZ
$22.2B
$3.79M 0.01%
25,267
-102,000
-80% -$15.8M
UHS icon
794
Universal Health Services
UHS
$9.43B
$3.79M 0.01%
+21,153
New +$4.35M
IONS icon
795
Ionis Pharmaceuticals
IONS
$9.35B
$3.75M 0.01%
50,000
-90,000
-64% -$7.1M
ANL
796
Adlai Nortye
ANL
$805M
$3.73M 0.01%
+538,461
New +$3.6M
CLX icon
797
Clorox
CLX
$11.6B
$3.61M 0.01%
34,853
-75,300
-68% -$8.54M
LMRI
798
Lumexa Imaging Holdings
LMRI
$1.05B
$3.6M 0.01%
418,528
-628,260
-60% -$8.62M
BBOT
799
BridgeBio Oncology
BBOT
$707M
$3.58M 0.01%
400,000
-1,000,000
-71% -$10.7M
TECH icon
800
Bio-Techne
TECH
$11.2B
$3.53M 0.01%
67,600
-305,636
-82% -$18.3M
30 31
32
33 34

Similar funds

Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Caisse de Depot et Placement du Quebec (CDPQ)
Caisse de Depot et Placement du Quebec (CDPQ) Montreal, Quebec, Canada $62.4B AUM 23.7% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $67.5B AUM 28.09% 1-Year Est. Return

Adage Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Adage Capital Partners held 1,116 positions worth $64.8B, down 1.9% from $66.1B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Adage Capital Partners's Q1 2026 filing shows 212 new, 277 increased, 389 reduced and 160 closed positions. Its largest new stake was Takeda Pharmaceutical: 6,424,984 shares worth $119M. The largest sale was Avidity Biosciences, an estimated $190M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.

  • Adage Capital Partners's largest Q1 2026 buy was Takeda Pharmaceutical: 6,424,984 shares worth $119M.
  • Adage Capital Partners added most to Revolution Medicines in Q1 2026, an estimated $330M increase.
  • Adage Capital Partners's biggest Q1 2026 reduction was Royalty Pharma, cutting an estimated $187M.
  • Adage Capital Partners fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Adage Capital Partners's ten largest holdings make up 28% of its $64.8B portfolio in Q1 2026.
  • Adage Capital Partners opened 212 new positions and closed 160 in Q1 2026.
  • Adage Capital Partners's portfolio value fell 1.9% quarter-over-quarter to $64.8B.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.